We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-9.51%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$486M
AUM Growth
+$102M
Cap. Flow
+$150M
Cap. Flow %
30.89%
Top 10 Hldgs %
40.72%
Holding
86
New
15
Increased
40
Reduced
9
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$21.9M
2
SNY icon
Sanofi
SNY
+$18.6M
3
CNC icon
Centene
CNC
+$16.6M
4
DXCM icon
DexCom
DXCM
+$15.2M
5
GH icon
Guardant Health
GH
+$14.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$15.5M
2
GMED icon
Globus Medical
GMED
+$13.3M
3
ACHC icon
Acadia Healthcare
ACHC
+$9.83M
4
AMED
Amedisys
AMED
+$6.89M
5
CI icon
Cigna
CI
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 97.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICLR icon
26
Icon
ICLR
$12.6B
$6.79M 1.4%
+31,311
New +$7.02M
QURE icon
27
uniQure
QURE
$3.21B
$6.58M 1.35%
353,106
+183,106
+108% +$2.91M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$6.57M 1.35%
130,000
-23,000
-15% -$1.35M
IRTC icon
29
iRhythm Holdings
IRTC
$4.08B
$6.2M 1.28%
57,403
-2,597
-4% -$344K
ONEM
30
DELISTED
1Life Healthcare
ONEM
$5.73M 1.18%
730,582
+230,582
+46% +$1.98M
MRNA icon
31
Moderna
MRNA
$24.1B
$5.71M 1.18%
+40,000
New +$5.72M
SGEN
32
DELISTED
Seagen Inc. Common Stock
SGEN
$5.54M 1.14%
31,311
-18,689
-37% -$2.69M
ZLAB icon
33
Zai Lab
ZLAB
$2.72B
$5.43M 1.12%
156,554
+81,554
+109% +$2.88M
AGL icon
34
Agilon Health
AGL
$1.7B
$5.04M 1.04%
9,226
+2,226
+32% +$1.13M
CRSP icon
35
CRISPR Therapeutics
CRSP
$5.19B
$4.86M 1%
80,010
-39,990
-33% -$2.35M
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
$4.48M 0.92%
99,150
+59,381
+149% +$2.71M
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.47M 0.92%
78,277
+38,277
+96% +$2.17M
ZBH icon
38
Zimmer Biomet
ZBH
$18.5B
$4.39M 0.9%
41,748
+11,748
+39% +$1.39M
NTLA icon
39
Intellia Therapeutics
NTLA
$1.67B
$4.32M 0.89%
83,495
+33,495
+67% +$1.7M
PTCT icon
40
PTC Therapeutics
PTCT
$6.22B
$4.19M 0.86%
104,656
+62,656
+149% +$2.2M
DVA icon
41
DaVita
DVA
$11.9B
$4.17M 0.86%
+52,184
New +$5.28M
TDOC icon
42
Teladoc Health
TDOC
$1.29B
$4.13M 0.85%
+124,369
New +$5.28M
ACRS icon
43
Aclaris Therapeutics
ACRS
$866M
$3.99M 0.82%
285,971
+47,971
+20% +$672K
REPL icon
44
Replimune Group
REPL
$1.14B
$3.83M 0.79%
219,194
+54,194
+33% +$890K
MIRM icon
45
Mirum Pharmaceuticals
MIRM
$5.99B
$3.45M 0.71%
177,427
+37,427
+27% +$883K
NVRO
46
DELISTED
NEVRO CORP.
NVRO
$3.43M 0.71%
78,277
+28,277
+57% +$1.55M
KRYS icon
47
Krystal Biotech
KRYS
$9.81B
$3.43M 0.7%
+52,184
New +$3.25M
JAZZ icon
48
Jazz Pharmaceuticals
JAZZ
$16.7B
$3.26M 0.67%
20,874
-14,126
-40% -$2.17M
ITOS
49
DELISTED
iTeos Therapeutics
ITOS
$3.23M 0.66%
156,553
+71,553
+84% +$1.7M
RETA
50
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.17M 0.65%
104,369
+69,369
+198% +$2.07M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Integral Health Asset Management held 86 positions worth $486M, up 27% from $384M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Integral Health Asset Management deployed $150M of net new capital in Q2 2022, opening 15 new positions and adding to 40 existing holdings. Its largest new stake was Eli Lilly: 73,059 shares worth $23.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $2.69M trimmed.

  • Integral Health Asset Management's largest Q2 2022 buy was Eli Lilly: 73,059 shares worth $23.7M.
  • Integral Health Asset Management added most to Centene in Q2 2022, an estimated $16.6M increase.
  • Integral Health Asset Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $2.69M.
  • Integral Health Asset Management fully exited Pfizer in Q2 2022, selling an estimated $15.5M.
  • Integral Health Asset Management's ten largest holdings make up 41% of its $486M portfolio in Q2 2022.
  • Integral Health Asset Management opened 15 new positions and closed 21 in Q2 2022.
  • Integral Health Asset Management's portfolio value rose 27% quarter-over-quarter to $486M.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.